Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04820842 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-994 in Adults With Narcolepsy
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT04820842 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 26 participants.
The verdict
NCT04820842, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in this study. The main aim of this study is to check if participants have side effects from TAK-994. Participants will take one of 3 different TAK-994 dose for 8 weeks. Then, half the participants will continue with their dose of TAK-994 and half will take a placebo. In this study, a placebo will look like a TAK-994 tablet but will not have any medicine in it. Participants will take TAK-994 or placebo for 4 weeks. Participants will visit the clinic for a final check-up 2 weeks after their last dose of TAK-994 or placebo. The study doctors will check for side effects from TAK-994 and placebo throughout the study. Participants will continue to record any narcolepsy symptoms as they did in Part B of the TAK 994-1501 study.
Interventions
- DRUG Placebo
- DRUG TAK-994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2021-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04820842
The ClinicalTrials.gov registry entry for NCT04820842 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04820842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04820842 about?
NCT04820842 is a clinical study titled "A Study of TAK-994 in Adults With Narcolepsy". Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in this study. The main aim of this study is to check if participants have side effects from TAK-994. Participants will take one of 3 different TAK-994 dose for 8 weeks. Then, half the participants will con...
What is the current status of trial NCT04820842?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-04-30. Estimated completion is 2021-11-03.
What interventions are being tested in trial NCT04820842?
The interventions under investigation include: Placebo (DRUG), TAK-994 (DRUG).
Who is sponsoring clinical trial NCT04820842?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.